Acesso livre
Acesso livre

Vacinas

Efetividade das vacinas Sputnik V, AstraZeneca e Sinopharm para o risco de infecção e morte por COVID-19 em idosos com mais de 60 anos na Argentina.

17 Mar, 2022 | 13:17h

Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study – The Lancet

Comentário: Evaluating COVID-19 vaccines in the real world – The Lancet

Tendências de tumores associados ao HPV, características demográficas e vacinação nos EUA, 2001-2017.

17 Mar, 2022 | 12:46h

Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017 – JAMA Network Open

Entrevista com o autor: Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations

Conteúdos relacionados:

[Not published yet] Single-dose HPV vaccine highly effective, researchers say – “Results of randomized controlled trial in Kenya bring new energy to eliminate cervical cancer worldwide”.

A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.

Three-year follow-up of 2-dose versus 3-dose HPV vaccine

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs

[Preprint] Alta efetividade da vacina contra Covid-19 grave em idosos na Finlândia antes e depois do surgimento da variante Ômicron.

15 Mar, 2022 | 13:22h

High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron – medRxiv

 

Comentário no Twitter

 

Outro estudo sugere que a 3ª dose de vacina é necessária para proteger as populações contra a variante Ômicron.

11 Mar, 2022 | 15:13h

Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study – The BMJ

Comunicado de imprensa: Third vaccine dose critical for protecting populations against omicron variant – BMJ Newsroom

 

Comentário no Twitter

 

OMS afirma que doses de reforço da vacina contra COVID são necessárias, revertendo recomendação anterior.

9 Mar, 2022 | 13:45h

WHO says COVID boosters needed, reversing previous call – Associated Press

 

Comentário no Twitter

 

[Comunicado de imprensa – ainda não publicado] Nova vacina da Sanofi e GSK demonstra forte proteção contra Covid-19 grave.

8 Mar, 2022 | 18:32h

Comentário: New vaccine demonstrates strong protection against severe Covid-19 in clinical trials – CNN

Comunicado de imprensa: Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine

M-A | Eficácia das vacinas contra Covid-19 em pacientes imunocomprometidos.

8 Mar, 2022 | 16:16h

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis – The BMJ

Comunicado de imprensa: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom

Conteúdos relacionados: Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.

 

Comentário no Twitter

 

Miocardite após vacinação com BNT162b2 contra COVID-19 entre adolescentes em Hong Kong.

3 Mar, 2022 | 16:38h

Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong – JAMA Pediatrics

Comentário: Study: Dosing change could reduce COVID-19 vaccine heart side effect in teens – UPI

Conteúdos relacionados:

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

[Preprint] Estudo mostra efetividade significativamente reduzida da vacina da Pfizer em crianças de 5 a 11 anos após o surgimento da variante Ômicron.

1 Mar, 2022 | 15:36h

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant – medRxiv

Comentários:

Pfizer Covid vaccine is less effective in kids 5 to 11, study finds – STAT

Pfizer Covid-19 vaccine effectiveness fell quickly for kids during Omicron surge but still offered some protection against severe disease – CNN

More mask mandates fall as poor COVID vaccine protection noted in young kids – CIDRAP

Estudo sugere que a síndrome inflamatória multissistêmica em crianças (MIS-C) é rara entre adolescentes vacinados.

25 Fev, 2022 | 14:22h

Reported cases of multisystem inflammatory syndrome in children aged 12–20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation – The Lancet Child & Adolescent Health

Comentários:

When vaccine adverse event reporting generates hope, not fear – The Lancet Child & Adolescent Health

MIS-C rare in COVID-vaccinated teens, study finds – CIDRAP

Vaccination Greatly Reduces Odds of MIS-C in Teens Who Get COVID – HealthDay

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.